Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Vera Therapeutics, Inc.NASDAQ: VERA
EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026
EPS (Basic) remains negative
Q2 FY2026 EPS (Basic) was -$1.52, compared with -$1.2 a year earlier. Trailing-twelve-month EPS (Basic) was -$5.86.
Context
- EPS (Basic) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 8 analysts of -$6.19 (-32.8%) for the fiscal year ending Dec 2026, a step up from the -69.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$1.52+10.1% QoQ
- Last fiscal yearDec 2025
- -$4.66-69.5% YoY
- LTMJun 2026
- -$5.86-58.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -26.7% | -21.8% | +4.9 pp |
| 1 year | -69.5% | -32.8% | +36.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (4.66) USD
- Year-over-year change
- -69.5%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.66) | -69.5% |
| FY2024 | 2024-12-31 | (2.75) | -22.2% |
| FY2023 | 2023-12-31 | (2.25) | +32.8% |
| FY2022 | 2022-12-31 | (3.35) | -37.9% |
| FY2021 | 2021-12-31 | (2.43) | — |
EPS (Basic) vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's LTM Jun 2026 EPS (Basic) of -$5.86 is the lowest of the 10 companies compared; the peer median is -$0.85.
- Its year-over-year change of -58.0% is the 9th highest of 10, against a peer median of +59.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $0.22 | +129.5% | — | |
| LTM Mar 2026 | $0.19 | +191.6% | -38.3% | |
| LTM Jun 2026 | -$0.13 | +96.0% | — | |
| LTM Mar 2026 | -$0.56 | +59.7% | — | |
| LTM Mar 2026 | -$0.85 | +82.7% | — | |
| LTM Mar 2026 | -$3.28 | +2.7% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$3.8 | +15.7% | — |
| LTM Mar 2026 | -$3.88 | -68.7% | — | |
| LTM Jun 2026 | -$4.64 | +39.4% | — | |
| LTM Jun 2026 | -$5.86 | -58.0% | — | |
| Peer median (excluding VERA) | -$0.85 | +59.7% | -38.3% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | (846K) | 0 | 0 | 0 |
| Gross Profit | 0 | 846K | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.48M | 69.84M | 78.23M | 126.17M | 215.26M |
| Selling, General & Admin | 11.92M | 21.91M | 23.79M | 41M | 100.22M |
| Operating Expenses | 34.4M | 91.75M | 102.01M | 167.17M | 315.47M |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| EBITDA | (32.41M) | (88.91M) | (92.18M) | (144.42M) | (291.62M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (34.4M) | (90.9M) | (102.01M) | (167.17M) | (315.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15K | 1.75M | 7.98M | 20.71M | 24.48M |
| Interest Expense | 20K | 992K | 3.79M | 7.63M | 7.53M |
| Other Income / Expenses | 1.79M | 1.85M | 6.02M | 15.02M | 15.86M |
| Income Before Tax | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K | 1K |
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| EPS (Diluted) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| Weighted Avg Shares | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Weighted Avg Shares (Diluted) | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.